PRACTICE Guidelines REGISTRATION PLATFORM
News MORE
  • 2023.0306

    The Development of Reporting Guideline of clinical Practice Guidelines in General Practice provides detailed guidance for the makers and writers of the general practice guidelines, which will further improve the reporting quality of the general practice guidelines, especially the Chinese general practice guidelines, and promote the application in general medical practice, thus finally improving the quality of primary medical care.

  • 2023.0220

    Professor Gordon Guyatt of McMaster University and Professor Victor Montori of the Mayo Clinic jointly published a paper in the British Medical Journal (BMJ) entitled: Guidelines should consider clinicians' time needed to treat on January 3, 2023.

  • 2022.1126

    IGEST is a generic tool for screening guidelines for any specialty, target population, and healthcare organization, but it is intended only as a screening tool, primarily for quickly assessing guideline quality and determining whether they can be adopted or adapted in other settings, and is not a substitute for some of the more complex guideline quality evaluation tools.

  • 2022.1031

    In July 2022, Jose F. Meneses-Echavez et al. from the Norwegian Institute of Public Health published an article in the Journal of Clinical Epidemiology entitled "Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations". The aim of this study was to identify and describe the processes suggested for the formulation of healthcare recommendations in healthcare guidelines available in guidance documents.

Register MORE
  • 2024.0621
    To address the therapeutic bottleneck of refractory immune hematologic diseases, the limited availability of many current drugs, and the advantages of mTOR inhibitors in the treatment of immune disorders, to improve the treatment of immune hematologic diseases in China, and to promote the standardization of clinical practice in order to help clinicians to treat immune hematologic diseases more accurately and, in particular, to optimize the use of mTOR inhibitors in the treatment of immune hematologic diseases.
  • 2024.0621
    For a long time, the pathological diagnosis of central nervous system (CNS) tumors were based on histology, playing an important role in the diagnosis, treatment, and prognosis evaluation of CNS tumors. Since the publicaition of the fifth edition of the WHO classification for central nervous system tumors in 2021, an increasing number of molecular signatures have been incorporated into the pathological integrated diagnosis of gliomas, becoming an indispensable part of daily pathological diagnosis. The application of integrated diagnosis and molecular signatures plays an important role in improving the objectivity and reproducibility of neuropathological diagnosis, improving individualized treatment, promoting clinical trials and basic research, but it also brings huge challenges to daily pathological diagnosis practice; The relevant molecular signaturess involve various forms of genetic variation, and there are differences in the results of different detection methods. There is a lack of expert consensus on the scope, technical limitations, and detection pathways of molecular detection for gliomas. Therefore, this consensus is jointly initiated and developed by experts in neuropathology and molecular pathology with rich theoretical and practical experience, aiming to provide comprehensive guidance and suggestions for the precise pathological diagnosis and treatment of gliomas.
  • 2024.0620
    With the recent development and improved accessibility of whole-body MRI (WB-MRI), this imaging technique has contributed significantly to the diagnosis, tumor burden evaluation, therapy response assessment and prognosis prediction in patients with MM. To standardize and guide the clinical application of WB-MRI in multiple myeloma (MM) in China, Chinese experts in the relevant fields drafted this expert consensus on the basis of comprehensive review of the literature and careful consideration for the clinical needs in China, so as to promote the popularization and standardized use of WB-MRI in MM.
Registration process and operational mode of a CPG registry